NCT03903133View on ClinicalTrials.gov

Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Sickle Cell Disease
Interventions
DRUG

Vitamin E

vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03903133 - Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients | Biotech Hunter | Biotech Hunter